Table. Pooled unadjusted odds ratio for the association between antimicrobial resistance and lethality by type of resistance, Latin America*.
| Type of resistance | OR (95% CI) | I2 |
|---|---|---|
| Carbapenem-resistance | 2.86 (2.07–3.95) | 61% |
| Extended-spectrum β-lactamase | 1.28 (0.95–1.74) | 38% |
| Methicillin-resistance | 1.78 (1.29–2.45) | 63% |
| MDRO† | 1.64 (1.16–2.30) | 68% |
| Azol-resistant | 1.41 (0.59–3.35) | - |
| Vancomycin-resistant | 4.09 (2.40–6.97) | 0% |
| Random effect model | 1.86 (1.55–2.23) | 71% |
*MDRO, multidrug-resistant organisms; OR, pooled odds ratio. †Multidrug-resistant organisms include methicillin-resistant Staphylococcus aureus, Vancomycin-resistant Enterococcus spp, extended-spectrum β-lactamase producing Enterobacterales, carbapenem-resistant Enterobacterales (including Klebsiella, Enterobacter, Escherichia coli, Proteus, Serratia), carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Acinetobacter baumannii and azole/echinocandin-resistant Candida spp.